TherapeuticsMD, Inc. (TXMD) Financial Statements (2026 and earlier)

Company Profile

Business Address 951 YAMATO ROAD, SUITE 220
BOCA RATON, FL 33431
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,733  5,7455,059 
Cash and cash equivalent7,733  5,7455,059 
Prepaid expense4311,3891,3151,4371,3041,450
Other undisclosed current assets6,28113,11412,1465,3305,89610,704
Total current assets:14,44514,50313,46112,51212,25912,154
Noncurrent Assets
Operating lease, right-of-use asset5,2935,5155,7325,9486,1026,302
Intangible asset, including goodwill, after accumulated amortization3,7613,9144,0434,1384,3214,428
Intangible asset, excluding goodwill, after accumulated amortization3,7613,9144,0434,1384,3214,428
Other noncurrent assets44447042821113058
Other undisclosed noncurrent assets13,71314,26914,84015,42716,01016,610
Total noncurrent assets:23,21124,16825,04325,72426,56327,398
TOTAL ASSETS:37,65638,67138,50438,23638,82239,552
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,1431,2061,0549457522,818
Accounts payable377263350176258234
Accrued liabilities7669437047694941,195
Other undisclosed accounts payable and accrued liabilities      1,389
Disposal group, including discontinued operation2,6672,6672,7222,7852,7812,924
Other undisclosed current liabilities9751,0728861,0111,633234
Total current liabilities:4,7854,9454,6624,7415,1665,976
Noncurrent Liabilities
Liabilities, other than long-term debt5,9956,2826,5506,7556,2866,482
Other liabilities873871832795744705
Operating lease, liability5,1225,4115,7185,9605,5425,777
Total noncurrent liabilities:5,9956,2826,5506,7556,2866,482
Total liabilities:10,78011,22711,21211,49611,45212,458
Equity
Equity, attributable to parent26,87627,44427,29226,74027,37027,094
Common stock111111111111
Additional paid in capital979,256979,205979,205979,204979,181979,157
Accumulated deficit(952,391)(951,772)(951,924)(952,475)(951,822)(952,074)
Total equity:26,87627,44427,29226,74027,37027,094
TOTAL LIABILITIES AND EQUITY:37,65638,67138,50438,23638,82239,552

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues8937849523931,761 
Sublease income527534376   
Cost of revenue
(Financing Interest Expense)
      (3)
Other undisclosed gross profit     8 
Gross profit:8937849523931,769(3)
Operating expenses(2,445)(1,646)(1,647)(1,264)(986)(1,406)
Other undisclosed operating income (loss)     (1,102)550
Operating loss:(1,552)(862)(695)(871)(319)(859)
Nonoperating income9729121,240203402292
Interest and debt expense (1)(3)(2)(2)  
Other undisclosed loss from continuing operations before equity method investments, income taxes     (10) 
Income (loss) from continuing operations before equity method investments, income taxes:(581)47543(670)74(567)
Other undisclosed income from continuing operations before income taxes 132210 
Income (loss) from continuing operations before income taxes:(580)50545(668)83(567)
Income tax benefit    32  
Other undisclosed income (loss) from continuing operations (32)   31 
Income (loss) from continuing operations:(612)50545(636)114(567)
Income (loss) from discontinued operations(7)1026(17)138(42)
Net income (loss) available to common stockholders, diluted:(619)152551(653)252(609)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(619)152551(653)252(609)
Comprehensive income (loss), net of tax, attributable to parent:(619)152551(653)252(609)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: